Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 14/20 | 0.57 |
| ▸ | CA2 | P00918 | 14/20 | 0.57 |
| ▸ | CA9 | Q16790 | 9/20 | 0.57 |
| ▸ | CA12 | O43570 | 7/20 | 0.57 |
| ▸ | CA4 | P22748 | 4/20 | 0.57 |
| ▸ | CA7 | P43166 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20707743 | 1.00 | CA1 (0.57) | CA1CA2CA9CA12CA4 | |
| SCHEMBL16845515 | 1.00 | CA1 (0.57) | CA1CA2CA9CA12CA4 | |
| SCHEMBL16820018 | 0.88 | SOS1 (0.51) | CA1CA2CA9CA12CA4 | |
| SCHEMBL16845435 | 0.88 | SOS1 (0.51) | CA1CA2CA9CA12CA4 | |
| SCHEMBL16845469 | 0.88 | CA1 (0.54) | CA1CA2CA9CA12CA4 | |
| SCHEMBL16820020 | 0.88 | CA1 (0.54) | CA1CA2CA9CA12CA4 | |
| SCHEMBL15443152 | 0.85 | NAMPT (0.48) | CA1CA2CA9CA12CA4 | |
| SCHEMBL15443153 | 0.85 | NAMPT (0.48) | CA1CA2CA9CA12CA4 | |
| SCHEMBL15443151 | 0.85 | NAMPT (0.48) | CA1CA2CA9CA12CA4 | |
| SCHEMBL16845520 | 0.84 | CHRNA7 (0.39) | CA1CA2CA9CA12CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2888229-B1 | alpha7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF | MERCK SHARP & DOHME (US) | 2019-02-06 | — | — | EP | disclosed |
| US-9790173-B2 | Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof-I | MERCK SHARP & DOHME CORP. (US) | 2017-10-17 | — | — | US | disclosed |
| CN-104884432-A | Alpha7 nicotinic acetylcholine receptor modulators and uses thereof-I | MERCK SHARP & DOHME | 2015-09-02 | — | — | CN | disclosed |
| US-20150175534-A1 | Alpha-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEROF-I | MERCK SHARP & DOHME CORP. | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175534-A1 | Alpha-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEROF-I | CHRNA7, CHRNA6, CHRNA5 | CA1 2274/4885CA2 2752/4885CA9 3757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.